Vendor Intelligence Report: Richards Biotech Simply Richards

Published 13 Jun 2026. 23-page investigative report on who is behind Richards Biotech Simply Richards: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Richards Biotech Simply Richards is a recent, thinly documented GLP-1 storefront with one useful lab signal and several accountability gaps. Across 1 Finnrick lab test, the vendor records 1 pass / 0 fail, a 100% overall pass rate. That pass belongs only to Tirzepatide, where the Finnrick rating is 79.62%; the full report explains why a single public-methodology pass is not repeat-batch confidence and why the result is methodology-sensitive under stricter scoring.

The product read is therefore narrow. Tirzepatide is the least unsupported choice in this catalog; Semaglutide and Retatrutide have no Simply Richards-specific Finnrick support in the supplied dataset. The tested Tirzepatide record also lacked a batch ID, while an industry red-list capture flags the vendor for unavailable COAs, making vial-to-test matching and recall logic weak.

The identity layer is unresolved. The site claims a Boynton Beach / South Florida facility, but the primary domain was registered through Wix in April 2025, Florida registry searches found no exact-name entity for Simply Richards or Richards Biotech, and site policies do not name an LLC, registered agent, owner, or responsible technical staff. A second domain traces to the same Wix site identifier, reducing copycat concern for that redirect while leaving operator opacity intact.

The main supply-chain lead points to ZZQ Peptides: an inferred sourcing relationship, not a proven ownership link. That matters because ZZQ’s Finnrick profile carries E (Bad) signals on relevant peptide/GLP-1 lines. Add Venmo/CashApp solicitation on the Tirzepatide product page, and the buyer issue becomes recourse and traceability, not just whether one sample passed.

Inside the full report:

  • Appendix A — Finnrick Laboratory Data for the single Tirzepatide test and methodology-divergence views
  • Florida Sunbiz searches and policy captures testing the Boynton Beach corporate-identity claim
  • Domain and Wix infrastructure analysis linking simplyrichards.com and simplyrichardspeptides.com
  • Supply-chain review of the ZZQ Peptides sourcing signal and upstream Finnrick ratings
  • COA and batch-traceability evidence, including the PRC Red List capture and missing batch-ID issue
  • Payment and fulfillment review covering Venmo/CashApp solicitation and USPS/UPS shipping terms

Risk assessment

  • Corporate-accountability risk — high: No Florida entity registration was found for Simply Richards/Richards Biotech; policies name no legal entity and ownership remains masked behind Wix/privacy/Gmail.
  • Traceability / COA risk — high: Peptide Resource Center lists Simply Richards with 'No COAs available'; field captures show the Finnrick Tirzepatide record lacked a batch ID.
  • Upstream-supplier reliability risk — high: Finnrick records indicate sourcing from ZZQ Peptides; ZZQ's Finnrick profile shows 'E' (Bad) ratings on multiple peptide/GLP-1 lines.
  • Tirzepatide single-sample / methodology-sensitivity risk — medium: The only Finnrick-tested product is Tirzepatide (1 test, 1 pass / 0 fail, 79.62%), leaving no repeat-batch confidence and sensitivity to stricter scoring.
  • Payment-recourse risk — medium: The Tirzepatide product page solicits Venmo/CashApp payment, reducing chargeback and buyer-protection options.